The art of virtualizing pharma R&D
- Today, virtualizing pharma R&D is increasingly related with data analytics and artificial intelligence (AI), technologies that have been developed by software companies outside the healthcare sector. The process of virtualizing pharma R&D is closely related to the technological advancements that result in the generation of large data sets ranging from genomics, proteomics, metabolomics, medical imaging, IoT wearables and large clinical trials, making it necessary for pharma companies to find new ways to store and ultimately analyze information. As a consequence, pharma companies are experimenting with AI in R&D ranging from in-silico drug design to clinical trail participants identification or dosage error reduction.
| Author of HS Reutlingen | Schuhmacher, Alexander |
|---|---|
| DOI: | https://doi.org/10.1016/j.drudis.2019.07.004 |
| Erschienen in: | Drug discovery today |
| Publisher: | Elsevier |
| Place of publication: | Amsterdam |
| Document Type: | Article |
| Language: | English |
| Year of Publication: | 2019 |
| Volume: | 24 |
| Issue: | 11 |
| Page Number: | 3 |
| First Page: | 2105 |
| Last Page: | 2107 |
| DDC classes: | 610 Medizin, Gesundheit |
| Open Access?: | Nein |
